Open AccessCalcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
Author(s) -
Uri S. Alon,
Rachel Levy-Olomucki,
Wayne V. Moore,
Jason R. Stubbs,
Shiguang Liu,
L. Darryl Quarles
Publication year - 2008
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.04981107
Subject(s) - cinacalcet , calcitriol , hypophosphatemia , endocrinology , medicine , parathyroid hormone , secondary hyperparathyroidism , phosphate , hyperparathyroidism , nephrocalcinosis , calcimimetic , fibroblast growth factor 23 , vitamin d and neurology , calcium , chemistry , kidney , biochemistry
The treatment for X-linked hypophosphatemia (XLH) with phosphate and calcitriol can be complicated by secondary hyperparathyroidism and nephrocalcinosis. Furthermore, vitamin D and phosphate stimulate FGF23 production, the pathogenic factor causing XLH. We investigated in XLH patients: 1) whether treatment with the calcimimetic agent, cinacalcet, will block the rise in parathyroid hormone (PTH) caused by phosphate administration; and 2) whether treatment with oral phosphate and calcitriol increases FGF23 levels.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom